Changes in Hong Kong stocks | Tiger Pharmaceuticals (03347) rose more than 7%, Citi said regulatory uncertainty eliminated and maintained positive visibility on the company's order growth and profit

The Zhitong Finance App learned that Tiger Pharmaceuticals (03347) rose more than 7% in the afternoon. As of press release, it had risen 7.63% to HK$44.64, with a turnover of HK$685.271 million.

According to the news, Citi released a research report stating that on Friday, Tiger Pharmaceuticals announced the findings of the China Securities Regulatory Commission's investigation against Tiger Pharmaceuticals co-founders Ye Xiaoping and Cao Xiaochun. Among them, the Zhejiang Regulatory Bureau plans to issue separate warnings and fines Ye and Cao of 500,000 yuan each. The investigation involved that he allegedly violated information disclosure obligations in changes in the company's shareholding. The results were consistent with Citibank's previous estimates and eliminated regulatory uncertainty. Furthermore, Citi maintained a positive view of Tiger Pharmaceuticals' order growth and profit visibility, and reaffirmed its “buy” rating and preferred stock status.